Compare FMC Corp (FMC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance

FMC stock trades at $8.31, down slightly by 0.12% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $2.24 billion in 2025, with negative profit margins and ROE, though recent quarterly EPS beat estimates. Analyst consensus is mixed with a price target of $14.20, and recent news highlights regulatory progress for its herbicide in Brazil and a minority equity investment by Tessenderlo Group.

The outlook remains challenged by high debt and cyclical industry headwinds, but aggressive deleveraging efforts and new product filings offer potential upside. Key risks include persistent losses, volatile cash flows, and competitive pressures in the agricultural sector, requiring careful monitoring of earnings recovery and debt reduction progress.

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.

Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.